Congress passes Ebola 'voucher' bill
This article was originally published in Scrip
The House and the Senate last week passed legislation aimed at adding Ebola to the list of qualified neglected tropical diseases for which biopharmaceutical makers can gain an FDA priority review voucher (PRV) if the firms develop drugs or vaccines to treat the deadly virus, which has infected more than 17,500 people and killed nearly 6,200 in the current outbreak.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.